G1 Therapeutics Phase 3 Trial Update: Market Response by Mark Eisenberg 13.02.2024 Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...